Literature DB >> 15814687

Signals from CD28 induce stable epigenetic modification of the IL-2 promoter.

Rajan M Thomas1, Ling Gao, Andrew D Wells.   

Abstract

CD28 costimulation controls multiple aspects of T cell function, including the expression of proinflammatory cytokine genes. One of these genes encodes IL-2, a growth factor that influences T cell proliferation, survival, and differentiation. Antigenic signaling in the absence of CD28 costimulation leads to anergy, a mechanism of tolerance that renders CD4+ T cells unable to produce IL-2. The molecular mechanisms by which CD28 costimulatory signals induce gene expression are not fully understood. In eukaryotic cells, the expression of many genes is influenced by their physical structure at the level of DNA methylation and local chromatin remodeling. To address whether these epigenetic mechanisms are operative during CD28-dependent gene expression in CD4+ T cells, we compared cytosine methylation and chromatin structure at the IL-2 locus in fully activated CD4+ effector T cells and CD4+ T cells rendered anergic by TCR ligation in the absence of CD28 costimulation. Costimulation through CD28 led to marked, stable histone acetylation and loss of cytosine methylation at the IL-2 promoter/enhancer. This was accompanied by extensive remodeling of the chromatin in this region to a structure highly accessible to DNA binding proteins. Conversely, TCR activation in the absence of CD28 costimulation was not sufficient to promote histone acetylation or cytosine demethylation, and the IL-2 promoter/enhancer in anergic cells remained completely inaccessible. These data suggest that CD28 may function through epigenetic mechanisms to promote CD4+ T cell responses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15814687     DOI: 10.4049/jimmunol.174.8.4639

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

1.  Conserved intergenic elements and DNA methylation cooperate to regulate transcription at the il17 locus.

Authors:  Rajan M Thomas; Hong Sai; Andrew D Wells
Journal:  J Biol Chem       Date:  2012-06-04       Impact factor: 5.157

Review 2.  Plasticity in programming of effector and memory CD8 T-cell formation.

Authors:  Ramon Arens; Stephen P Schoenberger
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

3.  Oct1 is a switchable, bipotential stabilizer of repressed and inducible transcriptional states.

Authors:  Arvind Shakya; Jinsuk Kang; Jeffrey Chumley; Matthew A Williams; Dean Tantin
Journal:  J Biol Chem       Date:  2010-11-04       Impact factor: 5.157

4.  Two-step binding of transcription factors causes sequential chromatin structural changes at the activated IL-2 promoter.

Authors:  Satoru Ishihara; Ronald H Schwartz
Journal:  J Immunol       Date:  2011-08-10       Impact factor: 5.422

Review 5.  GRAIL: a unique mediator of CD4 T-lymphocyte unresponsiveness.

Authors:  Chan C Whiting; Leon L Su; Jack T Lin; C Garrison Fathman
Journal:  FEBS J       Date:  2010-11-16       Impact factor: 5.542

Review 6.  Programming CD8+ T cells for effective immunotherapy.

Authors:  Christian S Hinrichs; Luca Gattinoni; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2006-04-17       Impact factor: 7.486

Review 7.  Cyclin-dependent kinases: molecular switches controlling anergy and potential therapeutic targets for tolerance.

Authors:  Andrew D Wells
Journal:  Semin Immunol       Date:  2007-03-23       Impact factor: 11.130

Review 8.  Transcriptional regulation of T cell tolerance.

Authors:  Sanmay Bandyopadhyay; Noemí Soto-Nieves; Fernando Macián
Journal:  Semin Immunol       Date:  2007-03-26       Impact factor: 11.130

Review 9.  Histone deacetylase inhibitors and transplantation.

Authors:  Ran Tao; Edwin F de Zoeten; Engin Ozkaynak; Liqing Wang; Bin Li; Mark I Greene; Andrew D Wells; Wayne W Hancock
Journal:  Curr Opin Immunol       Date:  2007-08-24       Impact factor: 7.486

10.  Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.

Authors:  Andrea Schietinger; Mary Philip; Varintra E Krisnawan; Edison Y Chiu; Jeffrey J Delrow; Ryan S Basom; Peter Lauer; Dirk G Brockstedt; Sue E Knoblaugh; Günter J Hämmerling; Todd D Schell; Natalio Garbi; Philip D Greenberg
Journal:  Immunity       Date:  2016-08-09       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.